{"prompt": "['Dermatology', 'beyond the skin', 'L', 'E', 'Cover Page', 'Official title: Tralokinumab in combination with topical corticosteroids for moderate to severe atopic', 'dermatitis ECZTRA 3 (ECZema TRAlokinumab trial no. 3)', 'LEO Pharma number: LP0162-1339', 'NCT number: NCT03363854', 'Date: 29-Aug-2018']['Updated Clinical Trial Protocol', 'LP0162-1339', 'Tralokinumab in combination with topical corticosteroids for', 'moderate-to-severe atopic dermatitis', 'ECZTRA 3 (ECZema TRAlokinumab trial no. 3)', 'Phase 3 - Efficacy and safety trial', 'A randomised, double-blind, placebo-controlled, phase 3 trial to evaluate the efficacy and', 'safety of tralokinumab in combination with topical corticosteroids in subjects with moderate-', 'to-severe atopic dermatitis who are candidates for systemic therapy', 'This clinical trial will be conducted in compliance with the clinical trial protocol, ICH-GCP', 'and the applicable regulatory requirements.', 'LEO Pharma A/S', 'Trial ID:', 'LP0162-1339', 'Date:', '29-Aug-2018', 'EudraCT No:', '2017-002065-21', 'Version:', '4.0', 'TMF-000005673 - Version 4.0']['Trial ID: LP0162-1339', 'Date: 29-Aug-2018', 'Version: 4.0', 'Page 2 of 129', 'Clinical trial protocol statements', 'Approval statement LEO Pharma A/S', 'The following persons have approved this clinical trial protocol by using electronic signatures', 'as presented on the last page of this document:', 'PPD', ', MSc Stat', 'Biostatistics Lead, Global Clinical Operations', 'PPD', ', MD, PhD', 'Medical Lead, Medical Sciences and Safety', 'PPD', ', RN, PhD', 'Clinical Operations Lead, Global Clinical Operations', 'Approval statement international coordinating investigator', 'The international coordinating investigator approves the clinical trial protocol and', 'consolidated clinical trial protocol(s) comprising any subsequent amendment(s) by manually', 'signing the International Coordinating Investigator Clinical Trial Protocol Approval Form,', 'which is a separate document adjoined to this document.', 'The following person has approved this clinical trial protocol:', 'Associate Professor Jonathan Silverberg, MD,', 'PhD, MPH', 'International coordinating investigator', 'Acknowledgement statement investigator(s)', 'Each participating investigator must agree to the approved clinical trial protocol and', 'consolidated clinical trial protocol(s) comprising any subsequent amendment(s) by signing', 'a', 'Clinical Trial Protocol Acknowledgement Form or a similar document.', 'TMF-000005673 - Version 4.0']\n\n###\n\n", "completion": "END"}